RYR2 – Medxy AI

Validated Risk Stratification for RYR2-Mediated Catecholaminergic Polymorphic Ventricular Tachycardia on Beta-Blocker Therapy

By MedXY 09/06/2026

This article reviews a validated clinical risk model predicting arrhythmic events in patients with RYR2-mediated CPVT receiving beta-blockers, facilitating personalized management to reduce life-threatening arrhythmias.

Cardiology news

Clinical Diagnosis of Calcium Release Deficiency Syndrome in a Family With Sudden Cardiac Death

By MedXY 07/10/2026

A 5-generation French Canadian family with history of sudden cardiac death was diagnosed with calcium release deficiency syndrome using a novel burst pacing provocation test, illustrating its clinical utility and highlighting the importance of pause-dependent arrhythmia detection.

Cardiology news

Precision Risk Assessment in CPVT: New Validated Models Predict Arrhythmic Events on Beta-Blocker Therapy

By MedXY 01/03/2026

A landmark study has developed and validated the first clinical risk prediction models for RYR2-mediated CPVT, identifying key factors like age at treatment and prior symptoms that determine life-threatening outcomes despite beta-blocker therapy.